drugset / Trial / NCT00742963

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

NCT00742963

Phase 1/2 Completed 107 enrolled ImmunoGenesis
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.

Timeline

Start
2008-08
Primary completion
2013-07
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Evofosfamide Other / unclassified 180 mg/m2 Intravenous
Subject Evofosfamide Other / unclassified 240 mg/m2 Intravenous

Indications